menu
    • menu

    Company profile for Ocugen

    NEW Drugs in Dev: 13
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for ocular Graft Versus Host Disease (oGVHD), if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases wi...
    Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for ocular Graft Versus Host Disease (oGVHD), if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OcugenUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5 Great Valley Parkway, Suite 160 Malvern, PA 19355
    Telephone
    Telephone
    484.328.4701
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ocugen.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ocugen
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Ocugen

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ocugen To Present At April 2026 Investor And Industry Conferences
    Ocugen To Present At April 2026 Investor And Industry Conferences

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279755/0/en/ocugen-to-present-at-april-2026-investor-and-industry-conferences.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Ocugen's CEO Wants To Bring Gene Therapy To The Masses
    Ocugen's CEO Wants To Bring Gene Therapy To The Masses

    16 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/eying-3-approvals-coming-years-ocugens-ceo-wants-bring-gene-therapy-masses

    FIERCE BIOTECH
    16 Apr 2026
    Share Share
    Ocugen Completes Dosing in Phase 2/3 Trial for Stargardt Disease
    Ocugen Completes Dosing in Phase 2/3 Trial for Stargardt Disease

    01 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/01/3266485/0/en/Ocugen-Announces-Early-Completion-of-Dosing-in-Phase-2-3-Pivotal-Confirmatory-Trial-of-OCU410ST-for-Stargardt-Disease.html

    GLOBENEWSWIRE
    01 Apr 2026
    Share Share
    Ocugen Eye Disease Gene Therapy Nabs Underwhelming Ph. 2 Win
    Ocugen Eye Disease Gene Therapy Nabs Underwhelming Ph. 2 Win

    24 Mar 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/ocugen-eye-disease-gene-therapy-nabs-full-ph-2-win-underwhelms-investors

    FIERCE BIOTECH
    24 Mar 2026
    Share Share
    Ocugen Webcast On March 24 To Review Ocu410 Phase 2 Trial Data
    Ocugen Webcast On March 24 To Review Ocu410 Phase 2 Trial Data

    23 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/23/3260257/0/en/Ocugen-to-Host-Webcast-on-Tuesday-March-24-at-8-a-m-EDT-to-Discuss-Phase-2-Clinical-Trial-Data-for-OCU410-Modifier-Gene-Therapy-for-Geographic-Atrophy.html

    GLOBENEWSWIRE
    23 Mar 2026
    Share Share
    Ocugen Updates Business With Q4 And Full Year 2025 Financials
    Ocugen Updates Business With Q4 And Full Year 2025 Financials

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249353/0/en/Ocugen-Provides-Business-Update-with-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search